| Clinical data | |
|---|---|
| Other names | L-Tyrosyl-D-alanyl-4-fluoro-L-phenylalanyl-L-phenylalaninamide |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C30H34FN5O5 |
| Molar mass | 563.630 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Frakefamide (INN) is asynthetic,fluorinated linear tetrapeptide with theamino acid sequence Tyr-D-Ala-(p-F)Phe-Phe-NH2 which acts as aperipherally-specific,selectiveμ-opioid receptoragonist.[1][2] Despite its inability to penetrate theblood-brain-barrier and enter thecentral nervous system,[1] frakefamide haspotentanalgesic effects and, unlike centrally-acting opioids likemorphine, does not producerespiratory depression, indicating that itsantinociceptive effects are mediated by peripheral μ-opioid receptors.[1][3] It was under development for the treatment ofpain byAstraZeneca andShire but was shelved afterphase IIclinical trials.[4][5]